C07C217/10

Phenalene-1-one-containing photosensitizer composition, phenalene-1-one compound and the use thereof
11186545 · 2021-11-30 · ·

A phenalene-1-one compound, a photosensitizer composition including the phenalene-1-one compound, an article including the phenalene-1-one compound and/or photosensitizer composition and the use thereof.

PHENALENE-1-ONE-CONTAINING PHOTOSENSITIZER COMPOSITION, PHENALENE-1-ONE COMPOUND AND THE USE THEREOF
20220064114 · 2022-03-03 ·

A phenalene-1-one compound, a photosensitizer composition including the phenalene-1-one compound, an article including the phenalene-1-one compound and/or photosensitizer composition and the use thereof.

PHENALENE-1-ONE-CONTAINING PHOTOSENSITIZER COMPOSITION, PHENALENE-1-ONE COMPOUND AND THE USE THEREOF
20200087259 · 2020-03-19 ·

A phenalene-1-one compound, a photosensitizer composition including the phenalene-1-one compound, an article including the phenalene-1-one compound and/or photosensitizer composition and the use thereof.

CRYSTALLIZATION METHODS USING FUNCTIONALIZED NANOPOROUS MATRICES AND RELATED SYSTEMS

Methods of forming crystals including, for example, methods of forming crystals using a nanoporous matrix, and associated materials, articles, and systems are generally provided. Advantageously, in some embodiments, the methods of forming crystals described herein provide crystal formation of a target molecule from a solution initially at an undersaturated state with respect to the target molecule. In some embodiments, a method involves obtaining a solution of a target molecule, where in some cases the solution is at an undersaturated state with respect to the target molecule; and exposing the solution to a functionalized nanoporous matrix under conditions that promote crystal formation of the target molecule. In some cases, the nanoporous matrix is functionalized with an antisolvent group.

CRYSTALLIZATION METHODS USING FUNCTIONALIZED NANOPOROUS MATRICES AND RELATED SYSTEMS

Methods of forming crystals including, for example, methods of forming crystals using a nanoporous matrix, and associated materials, articles, and systems are generally provided. Advantageously, in some embodiments, the methods of forming crystals described herein provide crystal formation of a target molecule from a solution initially at an undersaturated state with respect to the target molecule. In some embodiments, a method involves obtaining a solution of a target molecule, where in some cases the solution is at an undersaturated state with respect to the target molecule; and exposing the solution to a functionalized nanoporous matrix under conditions that promote crystal formation of the target molecule. In some cases, the nanoporous matrix is functionalized with an antisolvent group.

COMPOUND, CELLULAR VESICLE STAIN, AND METHOD FOR FLUORESCENT STAINING OF CELLULAR VESICLES
20240125678 · 2024-04-18 ·

The present invention addresses the problem of providing a new compound that binds specifically to intracellular and/or extracellular vesicles, a cellular vesicle stain, and a method for fluorescent staining of cellular vesicles.

The problem can be solved by a compound represented by formula (1).

##STR00001## (In formula (1), R.sub.1 represents H, a C.sub.1-C.sub.6 alkyl group, a hydroxy group, an amino group, or a carboxy group. R.sub.2 represents H, a C.sub.1-C.sub.18 alkyl group, a C.sub.1-C.sub.18 alkoxy group, a halogen element, NO.sub.2, or N(CH.sub.3).sub.2. R.sub.3 and R.sub.4 each independently represent H or CH.sub.3. However, R.sub.3 and R.sub.4 may bond to each other to form a ring, in which case R.sub.3 and R.sub.4 are CH.sub.2. 1 represents 1 or 2; m represents 0 or 1; and n represents 1, 2, or 3. Z represents a fluorescent group.)

COMPOUND, CELLULAR VESICLE STAIN, AND METHOD FOR FLUORESCENT STAINING OF CELLULAR VESICLES
20240125678 · 2024-04-18 ·

The present invention addresses the problem of providing a new compound that binds specifically to intracellular and/or extracellular vesicles, a cellular vesicle stain, and a method for fluorescent staining of cellular vesicles.

The problem can be solved by a compound represented by formula (1).

##STR00001## (In formula (1), R.sub.1 represents H, a C.sub.1-C.sub.6 alkyl group, a hydroxy group, an amino group, or a carboxy group. R.sub.2 represents H, a C.sub.1-C.sub.18 alkyl group, a C.sub.1-C.sub.18 alkoxy group, a halogen element, NO.sub.2, or N(CH.sub.3).sub.2. R.sub.3 and R.sub.4 each independently represent H or CH.sub.3. However, R.sub.3 and R.sub.4 may bond to each other to form a ring, in which case R.sub.3 and R.sub.4 are CH.sub.2. 1 represents 1 or 2; m represents 0 or 1; and n represents 1, 2, or 3. Z represents a fluorescent group.)

Phenalene-1-one-containing photosensitizer composition, phenalene-1-one compound and the use thereof
11987557 · 2024-05-21 · ·

A phenalene-1-one compound, a photosensitizer composition including the phenalene-1-one compound, an article including the phenalene-1-one compound and/or photosensitizer composition and the use thereof.

Styrenyl derivative compounds for treating ophthalmic diseases and disorders

The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are styrenyl derivative compounds, including but not limited to stilbene derivative compounds, and compositions comprising these compounds, that are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.

Styrenyl derivative compounds for treating ophthalmic diseases and disorders

The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are styrenyl derivative compounds, including but not limited to stilbene derivative compounds, and compositions comprising these compounds, that are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.